Globe Newswire10.01.18
Nemaura Medical Inc., a medical technology company developing sugarBEAT as a non-invasive glucose trending device for use by persons with diabetes and pre-diabetics, has expanded its manufacturing team with the appointments of Omar Farooq as project manager and David McLachlan as a project director, both of whom bring substantial expertise to the company.
Nemaura Medical CEO Dr. Faz Chowdhury commented, "We are delighted to have Omar and David join our team, and are confident in their combined ability to support and guide the company’s manufacturing scale-up from initial launch in the United Kingdom, to a global launch in multiple territories."
These appointments are intended to supplement Nemaura’s existing team of engineers, scientists and outsourced service providers as preparations continue for launch of sugarBEAT in the coming months.
Farooq is a chartered chemical engineer with 20 years of regulated industry experience across the full engineering lifecycle, including design, construction, commissioning, operation and process optimisation.
McLachlan will be directing the manufacturing and qualification strategy across multiple sites, to facilitate seamless transition into commercial launch and subsequently the scale up to support launches in multiple territories worldwide. He has an honors degree from Herriot Watt University, Edinburgh (England) and over 25 years of experience in the healthcare industry. Most recently, he played a pivotal role in creating the manufacturing capability for the launch of a new blood glucose monitoring strip for a leading test strip manufacturer. This work included developing business cases for various manufacturing options, vendor selection, and approval, and enhancing process throughput.
Nemaura Medical Inc. is a medical technology company developing sugarBEAT as a non-invasive, affordable and flexible glucose trending device for use by persons with diabetes and pre-diabetics.
SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five minute intervals over periods up to 24 hours.
SugarBEAT can additionally be used by insulin using persons with diabetes as an adjunctive glucose monitoring device when calibrated by a finger stick reading.
Nemaura Medical CEO Dr. Faz Chowdhury commented, "We are delighted to have Omar and David join our team, and are confident in their combined ability to support and guide the company’s manufacturing scale-up from initial launch in the United Kingdom, to a global launch in multiple territories."
These appointments are intended to supplement Nemaura’s existing team of engineers, scientists and outsourced service providers as preparations continue for launch of sugarBEAT in the coming months.
Farooq is a chartered chemical engineer with 20 years of regulated industry experience across the full engineering lifecycle, including design, construction, commissioning, operation and process optimisation.
McLachlan will be directing the manufacturing and qualification strategy across multiple sites, to facilitate seamless transition into commercial launch and subsequently the scale up to support launches in multiple territories worldwide. He has an honors degree from Herriot Watt University, Edinburgh (England) and over 25 years of experience in the healthcare industry. Most recently, he played a pivotal role in creating the manufacturing capability for the launch of a new blood glucose monitoring strip for a leading test strip manufacturer. This work included developing business cases for various manufacturing options, vendor selection, and approval, and enhancing process throughput.
Nemaura Medical Inc. is a medical technology company developing sugarBEAT as a non-invasive, affordable and flexible glucose trending device for use by persons with diabetes and pre-diabetics.
SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five minute intervals over periods up to 24 hours.
SugarBEAT can additionally be used by insulin using persons with diabetes as an adjunctive glucose monitoring device when calibrated by a finger stick reading.